SIGA Technologies (SIGA) Is Down 9.9% After Q1 Revenue Miss And Sharper Net Loss - What's Changed
SIGA Technologies experienced a 9.9% stock drop following a significant Q1 2026 revenue miss and a sharper net loss. The company reported revenue of US$6.24 million, down from US$7.04 million, and a net loss of US$3.45 million, compared to US$0.41 million the previous year. This performance highlights SIGA's vulnerability to inconsistent government contract timing and its impact on profitability and share price, despite management's readiness to return cash via special dividends.
We Think You Can Look Beyond SIGA Technologies' (NASDAQ:SIGA) Lackluster Earnings
Despite seemingly soft headline earnings, SIGA Technologies' shareholders may have reason for optimism due to positive underlying factors. The company's accrual ratio of -0.24 indicates that its free cash flow significantly exceeded its statutory profit, suggesting its earnings potential might be understated. While earnings per share fell, the strong conversion of profit to free cash flow is a positive indicator for the company.
We Think You Can Look Beyond SIGA Technologies' (NASDAQ:SIGA) Lackluster Earnings
Despite what appears to be lackluster earnings, SIGA Technologies, Inc.'s shareholders might have reasons to be optimistic. The company's strong accrual ratio of -0.24 indicates that its free cash flow significantly exceeded its statutory profit, suggesting that reported profits may actually understate its true earnings potential. This strong cash conversion ability could be a positive underlying factor balancing the softer headline numbers.
SIGA Technologies Q1 2026 Earnings: Minimal Deliveries, $13M TPOXX Order Expected in Q2 - News and Statistics
SIGA Technologies reported minimal product deliveries for Q1 2026 but anticipates a $13 million oral TPOXX order from an international customer and additional IV TPOXX deliveries to the Strategic National Stockpile (SNS) in Q2. CEO Diem Nguyen highlighted the company's commitment to global biological threat preparedness, emphasizing TPOXX's suitability for large-scale deployment. The company remains engaged with the U.S. government and expresses confidence in its long-term outlook despite quarterly variability.
Siga Technologies Q1 Earnings Call Highlights
Siga Technologies reported a first-quarter loss due to minimal product deliveries but anticipates an increase in Q2 from an international order and U.S. Strategic National Stockpile deliveries. CEO Diem Nguyen emphasized the company's focus on partnering with governments to address biological threats, particularly smallpox, with TPOXX. The company continues contract discussions with the U.S. government and is expanding international efforts, including a new agreement with Hikma for the Middle East and North Africa region.
SIGA: Q1 2026 revenue declined and net loss widened, but large TPOXX deliveries and global expansion are underway
SIGA Technologies Inc. experienced lower revenues and a wider net loss in Q1 2026 compared to the previous year. Despite this, the company anticipates major TPOXX deliveries in Q2 and Q3 and has expanded internationally through a special dividend payment and an exclusive MENA license agreement. This news was based on an SEC 8-K Current Report filed on May 7, 2026.
SIGA Technologies (NASDAQ: SIGA) Q1 loss, dividend and mpox label change
SIGA Technologies reported a challenging Q1 2026 with a net loss of $3.5 million due to declining revenue and rising costs, contrasting with a smaller loss and higher revenue in the prior year primarily due to the absence of international TPOXX® sales. Despite the financial dip, the company maintained a strong cash position of $145.6 million even after paying a special cash dividend of $0.60 per share. Regulatory news included the EMA recommending against Tecovirimat-SIGA's use for mpox, though its approval for smallpox and other orthopox indications remains, and the BARDA contract continues to present significant future revenue potential.
$39M in TPOXX shipments ahead as SIGA posts quarterly loss
SIGA Technologies (SIGA) reported a total revenue of $6.2 million and a net loss of $3.5 million for the first quarter of 2026, with product sales falling to $3.5 million from $5.8 million in the prior year. Despite the quarterly loss, the company anticipates delivering approximately $13 million of oral TPOXX in Q2 2026 to an international customer and $26 million of IV TPOXX to the U.S. Strategic National Stockpile by the end of Q3 2026. SIGA also announced an exclusive license agreement with Hikma for the MENA region and paid a special cash dividend of $0.60 per share in April 2026.
SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update
SIGA Technologies, Inc. reported financial results for the three months ended March 31, 2026, including a net loss of $3.5 million. The company is on track to deliver $13 million of oral TPOXX to an international customer and $26 million of IV TPOXX to the U.S. Strategic National Stockpile over the second and third quarters of 2026. Additionally, SIGA announced an exclusive license agreement with Hikma MENA FZE for commercialization of oral TPOXX in the MENA region and declared a special cash dividend of $0.60 per share.
SIGA (NASDAQ: SIGA) Q1 2026 revenue falls as net loss widens
SIGA Technologies reported a net loss of $3.5 million for Q1 2026, widening from $0.4 million in the prior-year quarter, as total revenues decreased to $6.2 million from $7.0 million. The decline was primarily driven by lower product sales and supportive services, coupled with higher operating expenses. The company also declared a special cash dividend of $0.60 per share, which significantly impacted current liabilities and stockholders' equity.
SIGA Technologies, Inc. Q1 2026 Earnings Call Summary
SIGA Technologies, Inc. discussed its Q1 2026 earnings, highlighting varied performance due to government procurement cycles but emphasizing long-term value from smallpox preparedness. The company outlined strategic initiatives including focusing on underrepresented regions, advancing its pediatric program, and targeting an FDA submission for Post-Exposure Prophylaxis (PEP). SIGA also addressed regulatory developments, such as the reaffirmation of TPOXX for core smallpox indications despite the withdrawal of the MPOXX indication, and continued special dividends despite revenue fluctuations.
SIGA CEO, CFO to discuss Q1 results and business update May 7
SIGA Technologies, Inc. (Nasdaq: SIGA) announced that its CEO Diem Nguyen and CFO Daniel Luckshire will host a webcast and conference call on Thursday, May 7, 2026, at 4:30 P.M. ET to provide a business update and discuss first-quarter 2026 financial results. The call will be accessible via live webcast on the company's website and through dial-in numbers, with a replay available for two weeks. Historically, similar announcements have been followed by mixed share reactions, averaging a -2.81% move.
Investors Purchase High Volume of Call Options on Siga Technologies (NASDAQ:SIGA)
Siga Technologies (NASDAQ:SIGA) experienced unusually high call option trading volume, with investors purchasing 1,200 call options, a 1,438% increase from the typical daily volume. This surge in options activity comes as several institutional investors have recently adjusted their holdings in the specialty pharmaceutical company. Siga Technologies' stock is currently trading down, with recent financial results reporting a loss per share and the company having declared a special dividend.
SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results
SIGA Technologies, Inc. announced that its management will host a webcast and conference call on Thursday, May 7, 2026, at 4:30 P.M. ET to provide a business update following the release of their first-quarter 2026 financial results. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire. A live webcast and replay will be available on the company's website.
SIGA TECHNOLOGIES INC SEC Filing
This article reports on a recent ARS SEC filing by SIGA Technologies Inc. (SIGA) on April 28, 2026. The filing has a low impact and neutral sentiment, and the full document is available as a PDF. The article also provides an overview of SIGA's stock data, rankings, latest news, and other recent SEC filings.
SIGA Technologies (SIGA) details 2026 virtual meeting, pay and plan votes
SIGA Technologies' 2026 Annual Meeting will be held virtually on June 9, 2026, where shareholders will vote on director elections, auditor ratification, executive compensation, and an amendment to increase shares available under the 2010 Stock Incentive Plan. In 2025, CEO Diem Nguyen's total compensation was $3,244,492, comprising salary, cash bonus, and stock awards, reflecting the company's pay-for-performance philosophy that ties executive compensation to corporate and individual performance. The company proposes adding 6.5 million shares to the incentive plan to attract and retain talent and align executive interests with stockholder value creation.
SIGA Technologies declares $0.60/share
SIGA Technologies has declared a cash dividend of $0.60 per share.
SIGA PE Ratio & Valuation, Is SIGA Overvalued
SIGA Technologies Inc. (SIGA) is considered overvalued, with its current forward P/E ratio of 57.47 significantly exceeding its five-year average of 8.92. The fair price for SIGA is estimated to be between $0.90 and $1.63, starkly contrasting its current price of $5.24, indicating it is overvalued by 220.92%. The company's P/S ratio of 1.74, despite being lower than the competitor average, is deemed unsustainable given its robust revenue decline of -95.34%.
The Technical Signals Behind (SIGA) That Institutions Follow
This article provides a technical analysis of Siga Technologies Inc. (NASDAQ: SIGA) for institutional followers. It outlines key findings, AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging), and a multi-timeframe signal analysis indicating near-term strong sentiment but neutral mid and long-term outlooks, with elevated downside risk.
Q3 2025 SIGA Technologies Inc Earnings Call Transcript
SIGA Technologies Inc. (SIGA) reported strong financial results for the first nine months of 2025, with $86 million in product revenue and a robust cash position of $172 million. Despite a net loss in Q3 2025, the company is actively engaged with the US government for future antiviral treatments and advancing its pipeline, including pediatric and post-exposure prophylaxis programs. Shareholder value commitment is evident through $230 million returned since 2020 via dividends and share buybacks, though concerns include questions from the EMA regarding product efficacy and potential delays due to the US government shutdown.
Siga Technologies Sees Unusually High Options Volume (NASDAQ:SIGA)
Siga Technologies (NASDAQ:SIGA) experienced unusually high options trading volume on Wednesday, with traders acquiring 1,200 call options, a 1,438% increase over average. This activity follows the company's declaration of a special dividend of $0.60 per share, payable on April 23rd to stockholders of record on April 7th. The specialty pharmaceutical company, known for its smallpox antiviral TPOXX, is currently rated "Hold" by analysts, and its stock is trading around $5.17 with a market capitalization of approximately $370.4 million.
SIGA Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for SIGA Technologies Inc. (SIGA), rating it a "Strong Sell" based on various technical indicators. It details moving averages, momentum indicators like RSI and MACD, and identifies key support and resistance levels for the stock. The analysis highlights that SIGA is trading below its significant moving averages, suggesting a bearish long-term trend.
SIGA SEC Filings - Siga Technologie 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Siga Technologie (SIGA) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It details SIGA's financial condition, business activities, and material events, with AI-powered summaries to highlight key information from lengthy documents. The article mentions recent filings like the Q3 2025 earnings press release and insider trading activities.
Does SIGA (SIGA)’s Repeat Special Dividend Reveal a Deeper Shift in Its Capital Allocation Priorities?
SIGA Technologies Inc. recently declared a special cash dividend of US$0.60 per share, payable on April 23, 2026, crediting its strong balance sheet and ongoing work on smallpox preparedness. This repeat dividend underscores management's confidence in cash reserves and their ability to return capital even during slower sales periods, despite the inherent risks associated with unpredictable government contract visibility. Investors are encouraged to consider the company's reliance on a limited number of government buyers and various fair value estimates when evaluating the stock.
SIGA Technologies declares $0.60/share
SIGA Technologies announced a dividend of $0.60 per share. This declaration comes after the company's Q4 2023 earnings report highlighted a significant beat on revenue and EPS. This dividend underscores the company's financial performance and shareholder return strategy.
SIGA Technologies Declares Special One-Time Cash Dividend
SIGA Technologies has announced a special one-time cash dividend of $0.60 per share, payable on April 23, 2026, to shareholders of record as of April 7, 2026. This decision reflects the company's financial flexibility and a shareholder-focused capital allocation strategy. Analysts currently rate SIGA as a Hold with a $5.00 price target, acknowledging its financial strength and positive earnings outlook, despite weak technicals.
Why Are Siga Technologies Shares Trading Higher?
SIGA Technologies (NASDAQ:SIGA) shares are trading higher after the company announced a special cash dividend of $0.60 per share, consistent with the previous year's dividend. Despite a generally down market and a struggling healthcare sector, SIGA's stock is experiencing a technical rebound, potentially attracting short-term dip buyers after reaching oversold conditions. The company's immediate strength is seen as stock-specific within a weak sector, with future catalysts including an estimated earnings report on May 7, 2026.
Why Are Siga Technologies Shares Trading Higher?
SIGA Technologies (NASDAQ: SIGA) shares are trading higher after the company declared a special cash dividend of $0.60 per share, payable in late April. This dividend announcement, consistent with last year's, comes despite broader market weakness and positions SIGA as an outperformer in the healthcare sector today. While the stock shows signs of a technical rebound from oversold conditions, its intermediate trend remains downward.
EMA Recommends Discontinuation of Tecovirimat for Mpox Treatment
The European Medicines Agency (EMA) expert panel has recommended discontinuing Tecovirimat for mpox treatment due to insufficient efficacy, as clinical trials showed no significant improvement in healing lesions or other disease outcomes compared to a placebo. While the drug remains authorized for other viral conditions like smallpox and cowpox, this decision highlights its limitations specifically for mpox. SIGA Technologies, the developer, is still pursuing global expansion and anticipates an EMA decision regarding smallpox in March 2026.
Siga Technologies Inc. Plans Dividend of $0.60 (NASDAQ:SIGA)
Siga Technologies Inc. (NASDAQ:SIGA) has declared a dividend of $0.60 per share, payable on April 23rd to shareholders of record on April 7th. The stock recently opened at $4.96 with a market cap of $355.35 million and a PE ratio of 16.00. Analysts project 1.04 EPS for the current year, and Weiss Ratings recently upgraded the stock to a "hold."
SIGA Technologies declares $0.60 special dividend per share By Investing.com
SIGA Technologies has announced a special cash dividend of $0.60 per share, payable on April 23, 2026, to shareholders of record on April 7, 2026. This dividend, matching the previous year's amount, reflects the company's strong balance sheet and commitment to shareholder value, despite the stock trading near its 52-week low. The pharmaceutical company, focused on infectious disease countermeasures, reported a Q4 2025 quarterly loss but an annual net income of $23 million with a solid cash balance.
SIGA Technologies declares $0.60 special dividend per share
SIGA Technologies (NASDAQ:SIGA) has announced a special cash dividend of $0.60 per share, payable on April 23, 2026, to shareholders of record by April 7, 2026. This dividend, matching the 2025 level, reflects the company's strong balance sheet and commitment to shareholder value, offering a 12% yield. Despite trading near its 52-week low and a recent quarterly loss, the company maintains a robust cash balance and is considered undervalued by InvestingPro.
SIGA Technologies declares $0.60 special dividend per share By Investing.com
SIGA Technologies, Inc. (NASDAQ:SIGA) has announced a special cash dividend of $0.60 per share, payable on April 23, 2026, to shareholders of record on April 7, 2026. This dividend matches the previous year's special dividend and reflects the company's strong balance sheet and focus on shareholder value, despite trading near its 52-week low. The company, a commercial-stage pharmaceutical firm, recently reported a Q4 2025 loss but demonstrated overall annual strength with a net income of $23 million and a solid cash balance.
SIGA Technologies (SIGA) General Counsel nets shares from RSU vesting
SIGA Technologies General Counsel Larry R. Miller reported the vesting of one-third of his previously granted restricted stock units, acquiring 6,920 shares of common stock. The company withheld 3,526 shares to cover tax obligations. Following these transactions, Miller directly holds 51,912 common shares, reflecting routine equity compensation rather than a market buy or sell.
SIGA Technologies declares $0.60/share
SIGA Technologies has declared a cash dividend of $0.60 per share. This declaration indicates a direct return of capital to shareholders. Further details about the record and payment dates would typically follow such an announcement.
SIGA Technologies Declares Special One-Time Cash Dividend
SIGA Technologies has announced a special one-time cash dividend of $0.60 per share, payable on April 23, 2026, to shareholders of record on April 7, 2026. This move highlights the company's financial flexibility and commitment to returning capital to shareholders. TipRanks' AI Analyst, Spark, rates SIGA as Neutral, citing solid financials but tempered by weak technicals.
[8-K] SIGA TECHNOLOGIES INC Reports Material Event
SIGA Technologies, Inc. has declared a special, one-time cash dividend of $0.60 per share of its common stock. This dividend is payable on April 23, 2026, to shareholders of record as of April 7, 2026. This action signifies a direct cash return to existing shareholders, separate from any regular dividend policy.
SIGA Declares Special Cash Dividend of $0.60 Per Share
SIGA Technologies, a commercial-stage pharmaceutical company, announced that its board of directors declared a special cash dividend of $0.60 per share on its common stock. This dividend, consistent with the previous year's special dividend, is payable on April 23, 2026, to shareholders of record on April 7, 2026. The company stated that this decision reflects its strong balance sheet and commitment to maximizing shareholder value.
SIGA Declares Special Cash Dividend of $0.60 Per Share
SIGA Technologies Inc. announced a special cash dividend of $0.60 per share, payable on April 23, 2026, to shareholders of record on April 7, 2026. This dividend, consistent with the previous year's, reflects the company's strong balance sheet and commitment to shareholder value. CEO Diem Nguyen highlighted the company's focus on executing its strategy and strengthening preparedness for potential smallpox outbreaks.
SIGA Declares Special Cash Dividend of $0.60 Per Share
SIGA Technologies Inc. has declared a special cash dividend of $0.60 per share, payable on April 23, 2026, to shareholders of record as of April 7, 2026. This decision reflects the company's strong balance sheet and commitment to maximizing shareholder value, according to CEO Diem Nguyen. SIGA, a commercial-stage pharmaceutical company, focuses on developing medicines for infectious diseases, particularly orthopoxviruses, and works with governments to enhance preparedness for outbreaks.
Earnings call transcript: SIGA Technologies Q4 2025 shows mixed market reaction
SIGA Technologies reported mixed results for Q4 2025, with an EPS loss of -$0.08 but a strong annual net income of $23 million and $155 million in cash. The stock experienced an after-hours dip of 2.23% but rebounded 4.53% in premarket trading. The company remains focused on government partnerships, particularly for its TPOXX product, and is navigating regulatory uncertainties in Europe while pursuing new development programs.
SIGA Technologies (SIGA) Is Down 11.2% After Mixed 2025 Results And Renewed Mpox Focus – Has The Bull Case Changed?
SIGA Technologies reported mixed Q4 2025 results with a revenue of US$3.8 million and a net loss of US$5.4 million, though full-year 2025 was profitable with US$94.57 million in revenue and US$23.28 million in net income. The company's stock fell 11.2% following these results, despite renewed attention on its smallpox-related antiviral portfolio due to a severe mpox case in New York City. The investment narrative for SIGA depends on its ability to navigate unpredictable government stockpiling and clinical trial outcomes for its niche antiviral products.
SIGA Technologies (SIGA) Is Down 11.2% After Mixed 2025 Results And Renewed Mpox Focus – Has The Bull Case Changed?
SIGA Technologies (SIGA) saw an 11.2% dip after posting mixed Q4 2025 results, with a significant revenue drop for the quarter, though full-year financials remained profitable. The confirmed severe mpox case in New York City has reignited interest in SIGA's smallpox-related antiviral products. Investors are now evaluating if this renewed focus and potential for new contracts can outweigh the impact of lumpy government orders and past trial setbacks for TPOXX.
Stock Traders Purchase Large Volume of Siga Technologies Call Options (NASDAQ:SIGA)
Investors purchased a significantly increased volume of call options for Siga Technologies (NASDAQ:SIGA) on Wednesday, indicating unusual bullish activity. Several large institutional investors also recently boosted their stakes in the company, which now has 55.4% institutional ownership. Siga Technologies reported a quarterly EPS of -$0.08 and currently holds a consensus "Hold" rating from analysts after a recent upgrade from "sell" to "hold" by Weiss Ratings.
U.S. Smallpox Treatment Market: See Incredible Growth
A new research report by Coherent Market Insights projects substantial growth for the U.S. Smallpox Treatment Market from 2026 to 2033. The report analyzes key market trends, drivers, challenges, and the competitive landscape, emphasizing technological innovation, pricing trends, and investment potential. Leading companies in this market include Siga Technologies, Bavarian Nordic, and Emergent BioSolutions.
SIGA Technologies (SIGA) General Counsel gets RSUs, pays taxes in shares
SIGA Technologies General Counsel Larry R. Miller reported routine equity compensation activity. On March 13, 2026, 21,261 restricted stock units vested and were settled, with 11,187 shares withheld to cover tax obligations. Miller also received a new grant of 68,060 restricted stock units, which will vest in three equal annual installments.
SIGA Technologies (SIGA) CFO awarded RSUs and shares on vesting
Daniel J. Luckshire, Executive Vice President & CFO of SIGA Technologies, reported routine equity compensation activities involving Restricted Stock Units (RSUs). This included the vesting of 11,503 common shares from a previous RSU grant and a new RSU award of 55,228 units. Additionally, 6,074 shares were withheld by the company to cover tax obligations associated with the RSU vesting.
SIGA Technologies (SIGA) CEO Diem Nguyen reports RSU grant and tax withholding
SIGA Technologies CEO Diem Nguyen reported equity compensation activity, including the vesting of restricted stock units (RSUs) into 85,045 common shares and a new grant of 272,243 RSUs. The company withheld 47,029 shares at $5.26 each to cover tax obligations related to the RSU vesting. Following these transactions, Nguyen directly owns 138,767 common shares and holds 272,243 RSUs.
SIGA Technologies (SIGA) EVP receives RSU grant and stock withheld for taxes
Dennis E. Hruby, EVP and Chief Scientific Officer of SIGA Technologies, reported routine equity compensation activity including the vesting of 11,445 restricted stock units (RSUs) and a new grant of 54,942 RSUs. To cover tax obligations, 3,955 shares were withheld at $5.26 per share. Following these transactions, Hruby directly holds 198,537 common shares.
CSM Advisors LLC Has $5.46 Million Stake in Siga Technologies Inc. $SIGA
CSM Advisors LLC significantly increased its stake in Siga Technologies Inc. (NASDAQ:SIGA) by 66.5% during the third quarter, bringing their total holdings to 596,512 shares valued at $5.46 million. Other institutional investors also adjusted their positions in SIGA, with the company's stock currently 55.40% owned by institutional investors and hedge funds. Siga Technologies, a specialty pharmaceutical company focused on medical countermeasures, recently reported quarterly earnings of ($0.08) per share and has a "Hold" rating from one analyst.
